A clinical trial of adjunctive oestrogen treatment in women with schizophrenia

Jayashiri Kulkarni; A. Riedel; A. R. De Castella; P. B. Fitzgerald; T. J. Rolfe; J. Taffe; H. Burger

doi:10.1007/s00737-002-0001-5

A clinical trial of adjunctive oestrogen treatment in women with schizophrenia

Jayashiri Kulkarni, A. Riedel, A. R. De Castella, P. B. Fitzgerald, T. J. Rolfe, J. Taffe, H. Burger

Research output: Contribution to journal › Article › Research › peer-review

59 Citations (Scopus)

Abstract

A double-blind, 28-day, placebo-controlled study was conducted with three groups of women of child-bearing age (N = 12 in each group) who received standardised antipsychotic medication plus a) 50 μg transdermal estradiol or b) 100 μg transdermal estradiol or c) transdermal placebo. Preliminary analyses show that women receiving 100 μg of estradiol made greater improvements in the symptoms of schizophrenia than either the 50 μg estradiol or placebo groups. The addition of 100 μg adjunctive transdermal oestrogen significantly enhanced treatment responsivity of acute, severe psychotic symptoms in women with schizophrenia. The positive impact of oestrogen treatment on psychotic symptoms via a multiplicity of possible actions (see accompanying articles in this issue) may prove clinically useful in the overall treatment of women with schizophrenia.

Original language	English
Pages (from-to)	99-104
Number of pages	6
Journal	Archives of Women's Mental Health
Volume	5
Issue number	3
DOIs	https://doi.org/10.1007/s00737-002-0001-5
Publication status	Published - 1 Nov 2002

Keywords

Dopamine
Oestrogen/estrogen
Prolactin
Schizophrenia
Serotonin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00737-002-0001-5

Cite this

@article{83b919930ae1476884dd9831a24d064d,

title = "A clinical trial of adjunctive oestrogen treatment in women with schizophrenia",

abstract = "A double-blind, 28-day, placebo-controlled study was conducted with three groups of women of child-bearing age (N = 12 in each group) who received standardised antipsychotic medication plus a) 50 μg transdermal estradiol or b) 100 μg transdermal estradiol or c) transdermal placebo. Preliminary analyses show that women receiving 100 μg of estradiol made greater improvements in the symptoms of schizophrenia than either the 50 μg estradiol or placebo groups. The addition of 100 μg adjunctive transdermal oestrogen significantly enhanced treatment responsivity of acute, severe psychotic symptoms in women with schizophrenia. The positive impact of oestrogen treatment on psychotic symptoms via a multiplicity of possible actions (see accompanying articles in this issue) may prove clinically useful in the overall treatment of women with schizophrenia.",

keywords = "Dopamine, Oestrogen/estrogen, Prolactin, Schizophrenia, Serotonin",

author = "Jayashiri Kulkarni and A. Riedel and {De Castella}, {A. R.} and Fitzgerald, {P. B.} and Rolfe, {T. J.} and J. Taffe and H. Burger",

year = "2002",

month = nov,

day = "1",

doi = "10.1007/s00737-002-0001-5",

language = "English",

volume = "5",

pages = "99--104",

journal = "Archives of Women's Mental Health",

issn = "1435-1102",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - A clinical trial of adjunctive oestrogen treatment in women with schizophrenia

AU - Kulkarni, Jayashiri

AU - Riedel, A.

AU - De Castella, A. R.

AU - Fitzgerald, P. B.

AU - Rolfe, T. J.

AU - Taffe, J.

AU - Burger, H.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - A double-blind, 28-day, placebo-controlled study was conducted with three groups of women of child-bearing age (N = 12 in each group) who received standardised antipsychotic medication plus a) 50 μg transdermal estradiol or b) 100 μg transdermal estradiol or c) transdermal placebo. Preliminary analyses show that women receiving 100 μg of estradiol made greater improvements in the symptoms of schizophrenia than either the 50 μg estradiol or placebo groups. The addition of 100 μg adjunctive transdermal oestrogen significantly enhanced treatment responsivity of acute, severe psychotic symptoms in women with schizophrenia. The positive impact of oestrogen treatment on psychotic symptoms via a multiplicity of possible actions (see accompanying articles in this issue) may prove clinically useful in the overall treatment of women with schizophrenia.

AB - A double-blind, 28-day, placebo-controlled study was conducted with three groups of women of child-bearing age (N = 12 in each group) who received standardised antipsychotic medication plus a) 50 μg transdermal estradiol or b) 100 μg transdermal estradiol or c) transdermal placebo. Preliminary analyses show that women receiving 100 μg of estradiol made greater improvements in the symptoms of schizophrenia than either the 50 μg estradiol or placebo groups. The addition of 100 μg adjunctive transdermal oestrogen significantly enhanced treatment responsivity of acute, severe psychotic symptoms in women with schizophrenia. The positive impact of oestrogen treatment on psychotic symptoms via a multiplicity of possible actions (see accompanying articles in this issue) may prove clinically useful in the overall treatment of women with schizophrenia.

KW - Dopamine

KW - Oestrogen/estrogen

KW - Prolactin

KW - Schizophrenia

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0036854211&partnerID=8YFLogxK

U2 - 10.1007/s00737-002-0001-5

DO - 10.1007/s00737-002-0001-5

M3 - Article

C2 - 12510212

SN - 1435-1102

VL - 5

SP - 99

EP - 104

JO - Archives of Women's Mental Health

JF - Archives of Women's Mental Health

IS - 3

ER -

A clinical trial of adjunctive oestrogen treatment in women with schizophrenia

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this